Related Experiment Video
Updated: Mar 6, 2026
09:52
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
8.1K
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G Wierda1, Andrew D Zelenetz2, Leo I Gordon3
1The University of Texas MD Anderson Cancer Center
Journal of the National Comprehensive Cancer Network : JNCCN
|March 10, 2017
Summary
Novel treatments, including targeted small molecule inhibitors and BCL-2 inhibitors, are advancing chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) care. These updates reflect new NCCN Guidelines for managing newly diagnosed and relapsed/refractory CLL/SLL.
Area of Science:
- Hematology
- Oncology
- Clinical Practice Guidelines
Background:
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are clinically indistinguishable lymphoid malignancies.
- Chemoimmunotherapy with novel CD20 monoclonal antibodies has been a cornerstone of CLL/SLL treatment.
- Emerging targeted therapies offer new avenues for patient management.
Purpose of the Study:
- To highlight recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for CLL/SLL.
- To provide insights into the latest treatment strategies for CLL/SLL based on new therapeutic advancements.
Main Methods:
- Review of recent clinical trial data and expert consensus on CLL/SLL treatment.
- Integration of findings into updated NCCN Guidelines for Oncology.
Main Results:
- Novel CD20 monoclonal antibodies have improved chemoimmunotherapy efficacy.
- Small molecule inhibitors targeting key signaling pathways show significant activity.
- BCL-2 family protein inhibitors demonstrate therapeutic benefit in CLL/SLL.
Conclusions:
- Current NCCN Guidelines incorporate advancements in targeted therapies for CLL/SLL.
- Updated guidelines offer evidence-based recommendations for newly diagnosed and relapsed/refractory CLL/SLL patients.
- These insights guide optimal treatment selection in the evolving landscape of CLL/SLL management.
More Related Videos
Related Concept Videos
01:16Primary Lymphoid Organs
16.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.3K
01:15Secondary Lymphoid Organs
9.9K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.9K
01:18Lymphoid Cells and Tissues
3.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.6K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:29Nursing Interventions II: Selecting and Classifying the Nursing Interventions
3.6K
Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
3.6K